HUM Quote, Financials, Valuation and Earnings

CVS Health Corp. has a net margin of 0.59% compared to Humana, Inc.'s net margin of -3.88%. Humana, Inc.'s return on equity of 7.3% beat CVS Health Corp.'s return on equity of 0.57%.

Humana, Inc. has a consensus price target of $288.46, signalling upside risk potential of 21.65%. On the other hand CVS Health Corp. has an analysts' consensus of $91.48 which suggests that it could grow by 17.57%. Given that Humana, Inc. has higher upside potential than CVS Health Corp., analysts believe Humana, Inc. is more attractive than CVS Health Corp..

Humana, Inc. has a beta of 0.421, which suggesting that the stock is 57.903% less volatile than S&P 500. In comparison CVS Health Corp. has a beta of 0.602, suggesting its less volatile than the S&P 500 by 39.787%.

Humana, Inc. has a quarterly dividend of $0.89 per share corresponding to a yield of 1.49%. CVS Health Corp. offers a yield of 3.42% to investors and pays a quarterly dividend of $0.67 per share. Humana, Inc. pays 35.45% of its earnings as a dividend. CVS Health Corp. pays out 72.76% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana, Inc. quarterly revenues are $32.6B, which are smaller than CVS Health Corp. quarterly revenues of $102.9B. Humana, Inc.'s net income of $194M is higher than CVS Health Corp.'s net income of -$4B. Notably, Humana, Inc.'s price-to-earnings ratio is 22.22x while CVS Health Corp.'s PE ratio is 203.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana, Inc. is 0.23x versus 0.25x for CVS Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Health Catalyst, Inc. has a net margin of 0.59% compared to Humana, Inc.'s net margin of -29.13%. Humana, Inc.'s return on equity of 7.3% beat Health Catalyst, Inc.'s return on equity of -30.29%.

Humana, Inc. has a consensus price target of $288.46, signalling upside risk potential of 21.65%. On the other hand Health Catalyst, Inc. has an analysts' consensus of $4.11 which suggests that it could grow by 81.51%. Given that Health Catalyst, Inc. has higher upside potential than Humana, Inc., analysts believe Health Catalyst, Inc. is more attractive than Humana, Inc..

Humana, Inc. has a beta of 0.421, which suggesting that the stock is 57.903% less volatile than S&P 500. In comparison Health Catalyst, Inc. has a beta of 1.641, suggesting its more volatile than the S&P 500 by 64.083%.

Humana, Inc. has a quarterly dividend of $0.89 per share corresponding to a yield of 1.49%. Health Catalyst, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humana, Inc. pays 35.45% of its earnings as a dividend. Health Catalyst, Inc. pays out -- of its earnings as a dividend. Humana, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana, Inc. quarterly revenues are $32.6B, which are larger than Health Catalyst, Inc. quarterly revenues of $76.3M. Humana, Inc.'s net income of $194M is higher than Health Catalyst, Inc.'s net income of -$22.2M. Notably, Humana, Inc.'s price-to-earnings ratio is 22.22x while Health Catalyst, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana, Inc. is 0.23x versus 0.49x for Health Catalyst, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Option Care Health, Inc. has a net margin of 0.59% compared to Humana, Inc.'s net margin of 3.61%. Humana, Inc.'s return on equity of 7.3% beat Option Care Health, Inc.'s return on equity of 15.16%.

Humana, Inc. has a consensus price target of $288.46, signalling upside risk potential of 21.65%. On the other hand Option Care Health, Inc. has an analysts' consensus of $35.30 which suggests that it could grow by 24.25%. Given that Option Care Health, Inc. has higher upside potential than Humana, Inc., analysts believe Option Care Health, Inc. is more attractive than Humana, Inc..

Humana, Inc. has a beta of 0.421, which suggesting that the stock is 57.903% less volatile than S&P 500. In comparison Option Care Health, Inc. has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.756%.

Humana, Inc. has a quarterly dividend of $0.89 per share corresponding to a yield of 1.49%. Option Care Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humana, Inc. pays 35.45% of its earnings as a dividend. Option Care Health, Inc. pays out -- of its earnings as a dividend. Humana, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana, Inc. quarterly revenues are $32.6B, which are larger than Option Care Health, Inc. quarterly revenues of $1.4B. Humana, Inc.'s net income of $194M is higher than Option Care Health, Inc.'s net income of $51.8M. Notably, Humana, Inc.'s price-to-earnings ratio is 22.22x while Option Care Health, Inc.'s PE ratio is 22.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana, Inc. is 0.23x versus 0.85x for Option Care Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

OptimizeRx Corp. has a net margin of 0.59% compared to Humana, Inc.'s net margin of 2.99%. Humana, Inc.'s return on equity of 7.3% beat OptimizeRx Corp.'s return on equity of 0.03%.

Humana, Inc. has a consensus price target of $288.46, signalling upside risk potential of 21.65%. On the other hand OptimizeRx Corp. has an analysts' consensus of $24.33 which suggests that it could grow by 49.32%. Given that OptimizeRx Corp. has higher upside potential than Humana, Inc., analysts believe OptimizeRx Corp. is more attractive than Humana, Inc..

Humana, Inc. has a beta of 0.421, which suggesting that the stock is 57.903% less volatile than S&P 500. In comparison OptimizeRx Corp. has a beta of 1.241, suggesting its more volatile than the S&P 500 by 24.096%.

Humana, Inc. has a quarterly dividend of $0.89 per share corresponding to a yield of 1.49%. OptimizeRx Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humana, Inc. pays 35.45% of its earnings as a dividend. OptimizeRx Corp. pays out -- of its earnings as a dividend. Humana, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana, Inc. quarterly revenues are $32.6B, which are larger than OptimizeRx Corp. quarterly revenues of $26.1M. Humana, Inc.'s net income of $194M is higher than OptimizeRx Corp.'s net income of $779K. Notably, Humana, Inc.'s price-to-earnings ratio is 22.22x while OptimizeRx Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana, Inc. is 0.23x versus 2.61x for OptimizeRx Corp.. Usually stocks with elevated PS ratios are considered overvalued.